VJOncology is committed to improving our service to you

BTOG 2020 | Real-world experience of Impower150 regimen for EGFR+ NSCLC

VJOncology is committed to improving our service to you

Sanjay Popat

The IMpower150 study (NCT02366143) showed that atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel improved progression-free survival and overall survival in patients with metastatic non-squamous non-small cell lung cancer (NSCLC), including those with EGFR mutations who failed TKI therapy. Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the IMpower150 regimen and reveals the importance of sharing early real-world clinical experiences. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter